BACKGROUND: Paclitaxel (BMS-181339: Taxol) is a promising agent against previously treated breast cancer. The antitumor activity of paclitaxel was evaluated using five human breast carcinoma xenografts in nude mice. METHODS: Paclitaxel at 20 mg/kg dissolved in 0.2 ml ethanol/cremophor EL solution was administered intraperitoneally daily for 5 days. RESULTS: Paclitaxel showed significant antitumor activity against MCF-7 and MX-1, but only limited activity against the other three xenografts (R-27, Br-10, and T-61), suggesting its substantially different antitumor spectrum from conventional antibreast cancer drugs. The different sensitivity of xenografts to paclitaxel was successfully reproduced in vitro using the MTT assay, when the cutoff concentration of paclitaxel was 20 microg/ml. CONCLUSION: Since no significant differences were observed in the pharmacokinetics of paclitaxel in sensitive and resistant tumor cell lines, the efficacy of this agent seemed to depend on the sensitivity of tumor cells rather than the intratumoral concentration of agent.
BACKGROUND:Paclitaxel (BMS-181339: Taxol) is a promising agent against previously treated breast cancer. The antitumor activity of paclitaxel was evaluated using five humanbreast carcinoma xenografts in nude mice. METHODS:Paclitaxel at 20 mg/kg dissolved in 0.2 ml ethanol/cremophor EL solution was administered intraperitoneally daily for 5 days. RESULTS:Paclitaxel showed significant antitumor activity against MCF-7 and MX-1, but only limited activity against the other three xenografts (R-27, Br-10, and T-61), suggesting its substantially different antitumor spectrum from conventional antibreast cancer drugs. The different sensitivity of xenografts to paclitaxel was successfully reproduced in vitro using the MTT assay, when the cutoff concentration of paclitaxel was 20 microg/ml. CONCLUSION: Since no significant differences were observed in the pharmacokinetics of paclitaxel in sensitive and resistant tumor cell lines, the efficacy of this agent seemed to depend on the sensitivity of tumor cells rather than the intratumoral concentration of agent.
Authors: F Asanuma; Y Yamada; E Kawamura; K Lee; H Kobayashi; T Yamada; T Suzuki; T Kubota Journal: Folia Microbiol (Praha) Date: 1998 Impact factor: 2.099
Authors: Limin Hu; Judith Hofmann; Charles Zaloudek; Napoleone Ferrara; Thomas Hamilton; Robert B Jaffe Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: Huan Meng; Yang Zhao; Juyao Dong; Min Xue; Yu-Shen Lin; Zhaoxia Ji; Wilson X Mai; Haiyuan Zhang; Chong Hyun Chang; C Jeffrey Brinker; Jeffrey I Zink; Andre E Nel Journal: ACS Nano Date: 2013-10-28 Impact factor: 15.881
Authors: S Giovinazzi; C R Lindsay; V M Morozov; E Escobar-Cabrera; M K Summers; H S Han; L P McIntosh; A M Ishov Journal: Oncogene Date: 2011-06-06 Impact factor: 9.867